Tag: Viatris Biosimilars

Biocon Biologics concludes integration of acquired biosimilars business in ~120 countries

Biocon Biologics, a unique, fully integrated, global biosimilars company with a rich portfolio of insulins and monoclonal antibodies, has successfully concluded the integration of the acquired Viatris biosimilars business with the transition of 10+ Emerging Markets and Japan, Australia and New Zealand in the final phase. All Viatris’ biosimilars brands, including Ogivri & Hertraz (bTrastuzumab), Abevmy (bBevacizumab), Fulphila (bPegfilgrastim), Hulio (bAdalimumab), Nepexto…

Biocon Biologics to acquire Viatris’ Biosimilars

Biocon Biologics Ltd., a subsidiary of Biocon Ltd., announced that it has entered into a definitive agreement with its partner Viatris Inc. Accordingly, Biocon Biologics Ltd. (BBL) will acquire Viatris’ biosimilars business to create a unique fully integrated global biosimilars enterprise. Viatris will receive consideration of up to USD 3.335 billion, including cash up to…